Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: A systematic review and meta-analysis

Jesus, Filipe Montes de; Kwee, Thomas C.; Nijland, Marcel; Kahle, X U; Huls, Gerwin; Dierckx, Rudi; Meerten, Tom van; Gheysens, Olivier; Dierickx, Daan; Vergote, Valentijn; Noordzij, Walter; Glaudemans, Andor W.J.M.

doi:10.1016/j.critrevonc.2018.09.007

Cited by 28 publications

(34 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The good diagnostic performance reported in this study suggests that 18 F-FDG PET/CT is a valuable imaging modality for detecting PTLD. These findings are in agreement with the results of previous published studies on the same topic [6][7][8] A recent evidence-based article reported that 18 F-FDG PET/CT is currently the most frequently investigated imaging modality for the diagnosis and staging of PTLD [9]. In this setting, 18 F-FDG PET/CT may contribute to confirm the clinical suspicion of PTLD identifying hypermetabolic targets for possible diagnostic biopsy.…”

supporting

confidence: 91%

“…In this setting, 18 F-FDG PET/CT may contribute to confirm the clinical suspicion of PTLD identifying hypermetabolic targets for possible diagnostic biopsy. Moreover, 18 F-FDG PET/CT may detect additional PTLD lesions compared to conventional imaging modalities in about 28% of cases, mainly in extranodal sites, resulting in possible disease upstaging [9]. Nevertheless, false-negative results (due to PTLD lesions located in anatomical regions with high physiological background activity and early PTLD lesions) and false-positive results (mainly due to inflammatory conditions or other tumors) of 18 F-FDG PET/ CT should be taken into account [9].…”

mentioning

confidence: 99%

“…Moreover, 18 F-FDG PET/CT may detect additional PTLD lesions compared to conventional imaging modalities in about 28% of cases, mainly in extranodal sites, resulting in possible disease upstaging [9]. Nevertheless, false-negative results (due to PTLD lesions located in anatomical regions with high physiological background activity and early PTLD lesions) and false-positive results (mainly due to inflammatory conditions or other tumors) of 18 F-FDG PET/ CT should be taken into account [9]. However, it should be underlined that some false-positive findings for PTLD at 18 F-FDG PET/CT, such as infections or other tumors, represent common complications after SOT or HCT; the detection of these findings in the post-transplant period by 18 F-FDG PET/CT is usually clinically relevant [10].…”

mentioning

confidence: 99%

“…Beyond diagnosis and staging of PTLD, 18 F-FDG PET/CT is emerging as a useful imaging modality to evaluate the treatment response in patients with PTLD. In this setting, 18 F-FDG PET/CT findings may alter or provide additional treatment guidance in 29% of cases [9]. Recent published data demonstrated that negative interim and/or negative end of treatment 18 F-FDG PET/CT may identify PTLD patients with low risk of disease recurrence, due to its high negative predictive value, providing clinically relevant information, in particular in patients with partial response based on conventional imaging evaluation [11,12].…”

mentioning

confidence: 99%

See 3 more Smart Citations

18F-FDG PET/CT in patients with post-transplant lymphoproliferative disorders: so far so good

Treglia

Ceriani

2019

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Post-transplant lymphoproliferative disorders (PTLD) are a heterogeneous group of lymphoproliferative diseases occurring after solid organ transplant (SOT) or allogeneic hematopoietic cell transplant (HCT). Epstein-Barr virus (EBV) serology mismatch among recipient and donor, type of transplanted organ, and intensity and type of immunosuppression are considered as established risk factors for developing PTLD. The risk is also higher among children compared with adults [1].According to the recent update of the WHO classification of tumors of hematopoietic and lymphoid tissues, PTLD are classified in early lesions (non-destructive PTLD), monomorphic PTLD (B cell, T cell, and NK cell subtype), polymorphic PTLD, and classical Hodgkin lymphoma PTLD. Monomorphic PTLD (in particular diffuse large B cell lymphoma) is the most frequent PTLD subtype [2]. Notably, PTLD is characterized by a high incidence of extranodal disease [1].As PTLD are serious post-transplant complications associated with significant morbidity and mortality, a timely and

show abstract

supporting

confidence: 91%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

18F-FDG PET/CT in patients with post-transplant lymphoproliferative disorders: so far so good

Treglia

Ceriani

2019

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…However, their study was performed between 2003 and 2010 with 43% of the study population scanned with a stand-alone PET system and no information on the duration of follow-up in negative cases. A recent systematic review on the clinical performance of different imaging modalities in the diagnosis and treatment response evaluation of PTLD patients reported FDG-PET(/ CT) to be the most frequently used imaging modality and a promising tool in this setting [24]. In the same review, false positive results were reported due to inflammatory conditions while false negative results occurred in areas of high physiological background activity and in non-destructive PTLD lesions.…”

Section: Current Guidelines From the British Committee For Standards mentioning

confidence: 99%

Diagnostic performance of FDG-PET/CT of post-transplant lymphoproliferative disorder and factors affecting diagnostic yield

Jesus

Kwee

Kahle

et al. 2019

Eur J Nucl Med Mol Imaging

Self Cite

View full text Add to dashboard Cite

Purpose Post-transplant lymphoproliferative disorder (PTLD) is a serious complication after solid organ and hematopoietic stem cell transplantation, requiring a timely and accurate diagnosis. In this study, we evaluated the diagnostic performance of FDG-PET/CT in patients with suspected PTLD and examined if lactate dehydrogenase (LDH) levels, Epstein-Barr virus (EBV) load, or timing of FDG-PET/CT relate to detection performance of FDG-PET/CT. Methods This retrospective study included 91 consecutive patients with clinical suspicion of PTLD and a total of 97 FDG-PET/CT scans within an 8-year period. Pathology reports and a 2-year follow-up were used as the reference standard. Diagnostic performance of FDG-PET/CT for detection of PTLD as well as logistic regression analysis for factors expected to affect diagnostic yield were assessed. Results The diagnosis of PTLD was established in 34 patients (35%). Fifty-seven FDG-PET/CT scans (59%) were true negative, 29 (30%) were true positive, 6 (6%) false positive, and 5 (5%) false negative. Sensitivity of FDG-PET/CT for the detection of PTLD was 85%, specificity 90%, positive predictive value 83%, and negative predictive value 92%, with good inter-observer variability (k = 0.78). Of the parameters hypothesized to be associated with a true positive FDG-PET/CT result for the diagnosis of PTLD, only LDH was statistically significant (OR 1.03, p = 0.04). Conclusion FDG-PET/CT has a good diagnostic performance in patients suspected of PTLD, with a good inter-observer agreement. Only LDH levels seemed to influence the detection performance of FDG-PET/CT. EBV-DNA load and timing of FDG-PET/CT after transplantation did not affect FDG-PET/CT diagnostic yield.

show abstract

Post‐Transplant Complications

Murugachandran,

Thomas,

Parmar

2023

Textbook of Transplantation and Mechanical Support for End‐Stage Heart and Lung Disease

View full text Add to dashboard Cite

Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: A systematic review and meta-analysis

Cited by 28 publications

References 60 publications

18F-FDG PET/CT in patients with post-transplant lymphoproliferative disorders: so far so good

18F-FDG PET/CT in patients with post-transplant lymphoproliferative disorders: so far so good

Diagnostic performance of FDG-PET/CT of post-transplant lymphoproliferative disorder and factors affecting diagnostic yield

Post‐Transplant Complications

Contact Info

Product

Resources

About